Bupleurum cytochrome P450 oxidase gene and application thereof

By identifying and using C-28 multi-step oxidation of β-Fragrance resin alcohol by using CYP716A41, the problem of obtaining C-28 is solved, and the analysis and synthesis of CYP716A41 of the Bupleurum cytochrome P450 oxidase gene is realized. Biological research has promoted the development of Bupleurum plant breeding.

CN118956912AActive Publication Date: 2024-11-15SOUTHWEAT UNIV OF SCI & TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411213524.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-15
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The existing technology has failed to effectively analyze the downstream synthesis pathways of Bupleurum saponin and the C-28-site hydroxylase in biosynthesis, resulting in difficulty in obtaining Bupleurum saponin and the acquisition process does not conform to the concept of green environmental protection.

Method used

Issuing and identifying the CYP716A41 CYC-Color Cytochrome P450 oxidase gene, CYP716A41, is used to catalyze the C-28 multi-step oxidation of β-Fragrance resin alcohol to produce high-root glycol and oleanolic acid, and promote the analysis of the biosynthesis pathway of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A41 of CYP716A412, which is used to catalyze the multi-step oxidation of CYP28-position of CYP28-position oxidation of β-Fragrance resin alcohol to produce high- Study research.

Benefits of technology

The heterologous production of the intermediate high-root diol of cyanulin synthesis of cyanulin has been realized, and the analysis and synthetic biology of the biosynthesis pathway of cyanulin has been promoted, and it has important research value and breeding application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956912A_ABST
    Figure CN118956912A_ABST
Patent Text Reader

Abstract

The invention provides a radix bupleuri cytochrome P450 oxidase gene and an application thereof. The gene is CYP716A41. Catalytic experiments prove that the enzyme has the functions of catalyzing saikosaponin to biologically synthesize an intermediate beta-amyrin and generating homoradical diol and oleanolic acid at C-28 site through multi-step oxidation. According to the present invention, with the application of the enzyme, the heterologous production of the saikoside synthesis intermediate homoradical diol is achieved, and the homoradical diol is the important synthesis intermediate of various C-28 hydroxylated oleanane saikoside and other C-28 hydroxylated site triterpenoid compounds; the invention further promotes biosynthetic pathway analysis and synthetic biology research of saikoside, and has important research value for synthesis regulation and control of oleanane pentacyclic triterpenoid compounds such as saikoside and the like and breeding of bupleurum plants.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological gene engineering, and in particular to a bupleurum cytochrome P450 oxidase gene and application thereof. Background Art

[0002] Saikosaponin, a triterpene compound, is the main active ingredient of the Bupleurum L. plant of the Apiaceae family. Saikosaponin a and Saikosaponin d are representative ingredients. Saikosaponin is a class of pentacyclic triterpene compounds. Studies have shown that saikosaponin has significant pharmacological effects such as antidepressant, anti-inflammatory, liver protection, anticancer, and immunomodulatory effects (Jiang N et al., Global traditional Chinese medicine, 2018, 11 (5): 796-800). It is the main active ingredient of the traditional Chinese medicine Bupleurum. The Chinese Pharmacopoeia stipulates that the total content of saikosaponin a and saikosaponin d in Bupleurum medicinal materials shall not be less than 0.3%. Each bag of Bupleurum dripping pills contains no less than 0.525 mg of Bupleurum in terms of saikosaponin a (C42H68O13). With the in-depth study of saikosaponin, saikosaponin will face a large demand. As a plant secondary metabolite, saikosaponin is present in a low content in the Bupleurum plant, and the main method of obtaining saikosaponin is still the extraction and separation of the medicinal plant Bupleurum. Bupleurum has a long growth cycle, and large-scale extraction and separation does not conform to the concept of green environmental protection. By analyzing the biosynthetic pathway of saikosaponin and using novel synthetic biology methods for heterologous synthesis, it is expected to obtain a large number of various saikosaponins in a green and environmentally friendly way.

[0003] At present, the genes of the upstream synthesis pathway of triterpenoid compounds in Bupleurum have been cloned and characterized, including squalene synthase BfSS1 (Kim YS et al., Planta, 2011, 233(2):343-55.). The key gene BcBAS1 for the synthesis of β-amyrin, the key parent nucleus of Bupleurum chinense, has been identified in tobacco (Mao Yanping et al., Identification and functional verification of members of the β-amyrin synthase gene family in Bupleurum chinense, Chinese Herbal Medicine, 2023, 54(11):3647-3654). However, there are no reports on the analysis of the downstream synthesis pathway of Bupleurum chinense and synthetic biology research. Among the 165 Bupleurum chinense saponins, 152 are oleanane-type Bupleurum chinense saponins produced from β-amyrin. Among the 151 oleanane-type Bupleurum chinense saponins, 101 are hydroxylated at the C-28 position ( Figure 1 The biosynthetic pathway of saikosaponin deduced by the present invention) is of great significance for further exploring the C-28 hydroxylase in the biosynthesis of saikosaponin and exploring its significance for the analysis of the biosynthetic pathway of saikosaponin and its biological synthesis methods. Summary of the invention

[0004] In order to further promote the analysis of the biosynthetic pathway of saikosaponins and the research on synthetic biology, the present invention is committed to exploring the key factors that catalyze the saikosaponin biosynthetic intermediate β-amyrin and further oxidize it in multiple steps at its C-28 position to produce erythrodiol and oleanolic acid, and then provide a bupleurum cytochrome P450 oxidase gene and its application. The bupleurum cytochrome P450 oxidase gene is CYP716A41, which has important research value for the synthesis and regulation of oleanane-type pentacyclic triterpene compounds such as saikosaponins.

[0005] In order to achieve the above technical objectives, the technical solutions adopted in this application are as follows:

[0006] In a first aspect, the present invention provides a Bupleurum cytochrome P450 oxidase gene, wherein the Bupleurum cytochrome P450 oxidase gene is from Chuanchai No. 2, and the CDS region nucleotides and CDS region nucleotide reverse complementary sequences of the Bupleurum cytochrome P450 oxidase gene are shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

[0007] In a second aspect, the present invention provides a Bupleurum cytochrome P450 oxidase gene, wherein the Bupleurum cytochrome P450 oxidase gene is from Chuanbei Chai No. 1, and the Bupleurum cytochrome P450 oxidase gene CDS region nucleotide and CDS region nucleotide reverse complementary sequence are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0008] In a third aspect, the present invention provides amino acids encoding the Bupleurum cytochrome P450 oxidase gene described in the first aspect, wherein the amino acids have a sequence shown in SEQ ID NO:1.

[0009] In a fourth aspect, the present invention provides amino acids encoding the Bupleurum cytochrome P450 oxidase gene of the second aspect, wherein the amino acids have a sequence shown in SEQ ID NO: 4. In a fifth aspect, the present invention provides an expression vector comprising the Bupleurum cytochrome P450 oxidase gene of the first aspect or the second aspect.

[0010] In a sixth aspect, the present invention provides a recombinant host cell comprising the Bupleurum cytochrome P450 oxidase gene described in the first aspect or the second aspect, or the expression vector described in the fifth aspect.

[0011] Preferably, the cell is selected from the group consisting of bacteria, fungal cells, insect cells, mammalian cells or plant cells.

[0012] In the seventh aspect, the present invention provides the use of the Bupleurum cytochrome P450 oxidase gene described in the first aspect or the second aspect, the amino acid described in the third aspect or the fourth aspect, the expression vector described in the fifth aspect, or the recombinant host cell described in the sixth aspect in catalyzing the hydroxylation reaction at C-28 of β-amyrin and / or catalyzing the carboxylation reaction at C-28 of erythrodiol.

[0013] In the eighth aspect, the present invention provides the use of the Bupleurum cytochrome P450 oxidase gene described in the first aspect or the second aspect, the amino acid described in the third aspect or the fourth aspect, the expression vector described in the fifth aspect, or the recombinant host cell described in the sixth aspect in the synthesis of erythrodiol and / or oleanolic acid and / or oleanane-type Bupleurum saponin.

[0014] In the ninth aspect, the present invention provides the use of the Bupleurum cytochrome P450 oxidase gene described in the first aspect or the second aspect, the amino acid described in the third aspect or the fourth aspect, the expression vector described in the fifth aspect, or the recombinant host cell described in the sixth aspect in Bupleurum plant breeding.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides a cytochrome P450 oxidase gene CYP716A41 of bupleurum, which is confirmed by catalytic experiments to have the function of catalyzing β-amyrin, an intermediate of saikosaponin biosynthesis, and producing erythrodiol and oleanolic acid in multi-step oxidation at its C-28 position. The present invention has realized the heterologous production of erythrodiol, an intermediate of saikosaponin synthesis, by using the enzyme, and erythrodiol is an important synthetic intermediate of various C-28 hydroxylated oleanane-type saikosaponins and other C-28 hydroxylated site triterpenoid compounds. The present invention further promotes the analysis of saikosaponin biosynthesis pathway and synthetic biology research, and has important research value for the synthetic regulation of oleanane-type pentacyclic triterpenoid compounds such as saikosaponins and the breeding of bupleurum plants. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0018] Figure 1 The figure is a derivation diagram of the biosynthetic pathway of saikosaponin of the present invention.

[0019] Figure 2The contents of 10 main saikosaponins in the roots and leaves of Sichuan Chai No. 2 and Sichuan North Chai No. 1 at mature stage in Example 1 of the present invention, wherein Figure a: saponin content in bupleurum root; Figure b: saponin content in bupleurum leaf; CC2: Sichuan Chai No. 2; CBC1: Sichuan North Chai No. 1; SSA: saikosaponin a; SSB2: saikosaponin b2; SSB3: saikosaponin b3; SSB4: saikosaponin b4; SSC: saikosaponin c; SSD: saikosaponin d; SSE: saikosaponin e; SSF: saikosaponin f; SSK: saikosaponin k; SSAC: 6"-O-acetyl saikosaponin a.

[0020] Figure 3 This is the analysis of the differentially expressed CYP450 gene family in Bupleurum chinense leaves in Example 1 of the present invention.

[0021] Figure 4 This is the agarose gel electrophoresis diagram of the CYP716A41 gene clone in Example 2 of the present invention (L1: Trans2K DNA Marker; L2: CYP716A41 gene band).

[0022] Figure 5 This is the plasmid map of pEAQ-CYP716A41 in Example 3 of the present invention.

[0023] Figure 6 This is the functional characterization of CYP716A41 in tobacco in Example 3 of the present invention, wherein Figure A is the TIC total ion current diagram of the GC-MS detection of the sample and the standard, and Figure B is a comparison diagram of the mass spectrum corresponding to the compound (black peak) and the standard mass spectrum (red peak); in the figure, 1, 2, and 3 are β-amyrin, erythrodiol, and oleanolic acid, respectively.

[0024] Figure 7 This is the characterization of the in vivo enzyme activity of CYP716A41 in tobacco in Example 4 of the present invention. DETAILED DESCRIPTION

[0025] The present invention is further described below in conjunction with specific examples. These examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In the following examples, if no special experimental methods are indicated, conventional conditions or conditions recommended by the manufacturer are usually used. In addition, any method and material similar or equivalent to the described content can be applied to the method of the present invention. The preferred implementation methods and materials described in the text are only for demonstration purposes of the present invention to show gene function.

[0026] The present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, which are intended to explain the present invention rather than to limit it.

[0027] The Bupleurum Root materials used in the following examples are from Longshan Farm of Southwest University of Science and Technology, and the public can obtain them from the Biomedical Innovation and Utilization Laboratory of Southwest University of Science and Technology.

[0028] RNAprep Pure Plant kit used in the embodiments of the present invention, One-Step gDNARemoval and cDNA Synthesis SuperMix, SalI and NotI restriction enzymes, -BasicSeamless Cloning and Assembly Kit, Trans2K DNA Marker, Escherichia coli competent cells, universal DNA purification and recovery kit, saikosaponin standard, 2×Rapid Taq Master Mix, GV3101 Agrobacterium competent cells, β-amyrin, erythrodiol, oleanolic acid, fecaltriol and trimethylsilyl imidazole / pyridine reagent are all commercially available products.

[0029] Example 1

[0030] This example conducts gene mining of Bupleurum CYP716A41, as follows:

[0031] Step 1, harvest the root and leaf tissues of mature Chuanchai No. 2 (Chuan Renyao 2023001) and Chuanbei Chai No. 1, quickly freeze them in liquid nitrogen and store them in an ultra-low temperature refrigerator at -80°C. Three biological replicates were set for each sample. Weigh 0.25g of sample in a 2mL centrifuge tube, grind with liquid nitrogen, and then vortex with 1.25mL of pre-frozen 80% methanol containing 0.1% formic acid (Thermo, USA) for 10 minutes. Incubate the sample on ice for 5 minutes, then centrifuge in a refrigerated centrifuge (Thermo, USA) at 4°C for 10 minutes at 8000 rpm. Dilute with mass spectrometry grade water to a methanol concentration of 53% in the sample solution. Subsequently, 500μL of the sample solution was transferred to a fresh Eppendorf tube and centrifuged for 10 minutes at 8000 rpm and 4°C. The external standard method was used to quantify saikosaponin a (SSA), saikosaponin b2 (SSB2), saikosaponin b3 (SSB3), saikosaponin b4 (SSB4), saikosaponin c (SSC), saikosaponin d (SSD), saikosaponin e (SSE), saikosaponin f (SSF), saikosaponin k (SSK) and 6"-O-acetylsaponin a (SSAC) in the samples. The saikosaponin standard reference substance was prepared into a mother solution with a mass concentration of 2.0 mg / mL using methanol solution, and the standard curve was prepared by gradient dilution.

[0032] Samples were quenched with ExionLC TMAD (SCIEX, USA) and The analysis was performed using a 6500+ mass spectrometer (SCIEX, USA) in negative ion mode (ESI-). The chromatographic column was ACQUITY UPLC BEH C18 (150 mm×3.0 mm, 1.7 μm, Waters). The injection volume was 0.5 μL, and the liquid phase gradient elution parameters were as shown in Table 1:

[0033] Table 1 Gradient elution parameters

[0034]

[0035] The following parameters were used for mass data acquisition: ion spray voltage -4500V, curtain gas pressure of 30psi, ion source gas 1 and ion source gas 2 pressures of 55psi, and turbine spray temperature of 600°C. The data files generated by HPLC-MS / MS were integrated and peak corrected using SCIEX OS version 1.4, and the key parameters were set as follows: signal-to-noise ratio, 10; minimum peak height 500; Gaussian smoothing width, 3. The peak area represents the relative content of the corresponding substance.

[0036] Step 3, take the above-mentioned Chuanchai No. 2 and Chuanbeichai No. 1 samples stored in a -80°C refrigerator, use RNAextraction kit (TIANGEN, China), according to the kit instructions, extract total RNA from four Bupleurum tissue samples. The extracted RNA was quantitatively and quality tested using Nanodrop and Qubit (Agilent, USA), and an external company (Novogene, China) was commissioned for RNA sequencing. Combined with the above-mentioned saponin metabolism test results, CYP450 candidate genes were screened from the transcriptome sequencing results.

[0037] Step 4: Using the Arabidopsis thaliana.L CYP450s family classification data (https: / / phytozome-next.jgi.doe.gov / ) as a reference, the screened CYP450 candidate genes were identified as gene families. Cluster analysis was performed using the maximum likelihood method using IQ-TREE (2.1.4beta) software, with GTRGAMMA selected as the model and Bootstrap set to 1000. Finally, the constructed phylogenetic tree was visualized on the ITOL website (https: / / itol.embl.de / ).

[0038] The results are as follows Figure 2As shown in the figure, the contents of 8 major saikosaponins in the leaves of Chuanchai 2 were significantly higher than those in Chuanbei Chai 1 (Figure b), and the contents of 6 major saikosaponins in the roots of Chuanchai 2 were significantly higher than those in Chuanbei Chai 1 (Figure a). Based on this, 53 CYP450 genes with higher expression levels in the leaves of Chuanchai 2 than in Chuanbei Chai 1 and expressed in the roots of the two Bupleurum species were screened out from the transcriptome sequencing results. The identification results of these CYP450s gene families are shown in Figure 2. Figure 3 As shown. These genes belong to 6 CYP450 subfamilies. Among them, 11 genes in the CYP85 family can be further divided into 5 subfamilies. BC_032098 belongs to the CYP716 subfamily in the CYP85 family. Literature shows that members of the CYP716 family are the main contributors to the diversity of triterpenoid biosynthesis in dicotyledonous plants (Miettinen, K et al., The ancient CYP716 family is a major contributor to the diversification of eudicot triterpenoid biosynthesis. Nat Communication 8, 14153 (2017)). Therefore, this gene was selected for subsequent research. The gene was submitted to the International P450 Nomenclature Committee (Nelson's nomenclature) (http: / / drnelson.uthsc.edu / cytochromeP450.html) for naming, and BC_032098 was named CYP716A41.

[0039] Example 2

[0040] This example clones the CYP716A41 gene of Chuanchai No. 2 and Chuanbeichai No. 1, as follows:

[0041] Step 1: Use RNAprep Pure Plant kit (Quanshijin) to extract total RNA from Bupleurum chinense No. 1 and Bupleurum chinense No. 2 plants according to the kit instructions.

[0042] Step 2, then use One-Step gDNA Removal and cDNA SynthesisSuperMix (Full Gold) Reverse Transcription Kit, reverse transcribe the total RNA according to the kit instructions to obtain cDNA, the reverse transcription system is shown in Table 2 below:

[0043] Table 2 Reverse transcription system

[0044]

[0045]

[0046] Take 1 μL of the obtained cDNA solution and use 1% agarose gel to detect the reverse transcription effect, and store the remaining solution in a -20°C refrigerator.

[0047] Step 3, finally, full-length gene cloning and product purification:

[0048] According to the full-length cDNA sequence of the CYP450 gene in the transcriptome, specific primers for full-length cloning (F: GAGCTTGCTAGATGATGATGTA (SEQ ID NO: 7), R: TCAATCTATGGTTTGTGAGGAA (SEQ ID NO: 8)) were designed and 2× FastPfu PCR SuperMix (-dye) (full gold) was used for PCR reaction. The reaction system was as follows:

[0049] PCR reaction conditions: 95℃2min; 95℃20s, 51℃20s, 72℃30s 35 cycles; 72℃5min; 4℃ hold. After the reaction, take 5μL of the reaction product, add 1μL 6×Loading Buffer, and perform 1.0% agarose gel electrophoresis (160V, about 20min). After the target band position is detected, use 0.8% agarose gel electrophoresis (160V, about 20min) to fully separate the DNA and cut the target band. The agarose gel electrophoresis results of CYP716A41 gene cloning are shown in Figure 1. Figure 4 shown.

[0050] The target gene was recovered and purified according to the operating manual of the universal DNA purification and recovery kit (Tiangen), and the target gene was CYP716A41, wherein the amino acid sequence of the CDS region, the nucleic acid sequence of the CDS region, and the reverse complementary sequence of the nucleic acid sequence of the CDS region of the CYP716A41 gene of Chuanchai No. 2 are shown in SEQ ID NO: 1 to SEQ ID NO: 3, respectively, and the amino acid sequence of the CDS region, the nucleic acid sequence of the CDS region, and the reverse complementary sequence of the nucleic acid sequence of the CDS region of the CYP716A41 gene of Chuanbei Chai No. 1 are shown in SEQ ID NO: 4 to SEQ ID NO: 6, respectively (Table 3).

[0051] Table 3 The amino acid, nucleic acid and reverse complementary sequences of CDS of CYP716A41 of Chuanchai 2 and Chuanbeichai 1

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058] Example 3

[0059] The CYP716A41 gene was functionally identified as follows:

[0060] (1) Construction of pEAQ-CYP716A41 vector

[0061] Based on the CYP716A41 sequence, homology arm primers were designed (Table 4).

[0062] Table 4 Homologous arm primer sequences

[0063]

[0064]

[0065] Using the gene fragment of CYP716A41 collected in Example 2 as a template, reagents were added to the PCR tube according to the reaction system in Table 5 below:

[0066] Table 5 Reaction system

[0067]

[0068] PCR reaction conditions: 98℃3min; 98℃10s, 58℃5s, 72℃30s 34 cycles; 72℃1min; 4℃ hold. After the reaction, take 5μL of the reaction product, add 1μL 6×Loading Buffer, and perform 1.0% agarose gel electrophoresis (160V, about 20min). After the target band position is detected, use 0.8% agarose gel electrophoresis (160V, about 20min) and gel recovery kit to purify and recover DNA.

[0069] Linear vector preparation: Use SalI enzyme and NotI enzyme (full gold) to double-digest the plant binary transient expression vector pEAQ-HT-DEST1 to obtain a linear vector. Add reagents to the PCR tube according to the reaction system in Table 6:

[0070] Table 6 Reaction system

[0071]

[0072] The reaction conditions were 37°C for 15 min and 65°C for 20 min. After the reaction, 5 μL of the reaction product was taken, 1 μL of 6× Loading Buffer was added, and 1.0% agarose gel electrophoresis (160 V, 20 min) was performed. After the target band position was detected correctly, 0.8% agarose gel electrophoresis (160 V, 20 min) and gel recovery kit were used to purify and recover the DNA.

[0073] The target fragment CYP716A41 and the linear vector were connected into a ring, and the seamless splicing method (homologous recombination principle) was used. -Basic Seamless Cloning and Assembly Kit (Quanshijin) was used to construct the eukaryotic expression vector pEAQ-CYP716A41. The concentration of the target gene fragment and the vector fragment was detected by a nucleic acid quantifier, and the target fragment and the vector fragment were prepared into a reaction system at a molar ratio of 2:1. After adding an equal volume of 2×Basic Assembly Mix, the mixture was fully mixed and reacted at 50°C for 15 minutes. The reaction solution was mixed with 50μL TransTI Escherichia coli clone competent cells, allowed to stand on ice for 30 minutes, heat-shocked in a 42°C water bath for 30 seconds, allowed to stand on ice for 2 minutes, 500μL LB liquid culture medium without antibiotics was added, incubated at 37°C and 200rpm for 1 hour, centrifuged at 4600g for 1 minute, 100μL of the supernatant was retained to resuspend the bacteria, and evenly spread on a plate containing 50mg·L -1 The culture was carried out on LB solid medium containing kanamycin at 37°C in the dark for 16 hours. After colony screening, the bacterial solution cultured at 37°C and 200 rpm in the dark for about 3-4 hours was used as a template, and the primers PEAQ-F (CGAACTTGGAGAAAGATTGT, SEQ ID NO: 11) and PEAQ-R (CGCTCACCAAACATAGAAA, SEQ ID NO: 12) were used for positive clone verification, and the bacterial solution containing the target band was sent for sequencing to obtain the pEAQ-CYP716A41 eukaryotic expression vector. The plasmid map is shown in Figure 5 shown.

[0074] The same method was used to construct tHMGR and BcBAS1 into the SalI and XhoI sites of the pEAQ-CYP716A41 eukaryotic expression vector pEAQ, and the pEAQ-tHMGR and pEAQ-BcBAS1 eukaryotic expression vectors were obtained. tHMGR is a truncated 3-hydroxy-3-methylglutaryl coenzyme A reductase gene (HMG-CoA) from Paris polyphylla (Yin X et al., Metabolic Engineering, 2023; 76: 232–246). BcBAS1 is a β-amyrin synthase gene from Bupleurum chinense (Mao Yanping et al., Identification and functional verification of β-amyrin synthase gene family members from Bupleurum chinense, Chinese Herbal Medicine, 2023, 54(11): 3647-3654).

[0075] (2) Transformation of Agrobacterium tumefaciens

[0076] Slightly thaw the GV3101 Agrobacterium competent cells stored at -80°C in the palm of your hand. When they are half-thawed, quickly place them in ice water.

[0077] 100 μL of competent cells were mixed with 1 μg of plasmid DNA and mixed evenly by tapping the bottom of the tube. Next, the mixture was first placed in an ice bath for 5 minutes, then transferred to liquid nitrogen for 5 minutes, then incubated in a 37°C water bath for 5 minutes, and finally returned to the ice bath for 5 minutes.

[0078] 500 μL of antibiotic-free LB liquid medium was added to the centrifuge tube, and then cultured in a shaking incubator at 28° C. for 2 hours.

[0079] Centrifuge at 6000 rpm for one minute to collect the bacteria, retain about 100 μL of the supernatant, gently blow to resuspend the bacteria, spread it on the LB plate containing the corresponding antibiotics, and place it upside down in a 28°C incubator for 2-3 days.

[0080] A single colony was randomly picked and placed in 1 mL of LB liquid medium, and cultured at 30°C and 200 rpm for 36-48 h;

[0081] Positive strain test: Take 1 μL of bacterial solution for positive clone PCR reaction to detect whether the plasmid has successfully transformed into GV3101 Agrobacterium. Add the following to the PCR tube according to the reaction system in Table 7:

[0082] Table 7 Reaction system

[0083] name Addition volume (μL) 2× Rapid Taq Master Mix 10 Bacterial liquid 1 PEAQ-F 1 PEAQ-R 1 ddH2O 7

[0084] The reaction procedure was 95°C, 3 min; 95°C 15 s, 56°C 15 s, 72°C 0.5 min, 35 cycles of 9; 72°C, 5 min; 4°C to stop the reaction. After the reaction, 8 μL of the reaction product was subjected to 1.0% agarose gel electrophoresis (180 V, about 10 min) with Trans2K DNA Marker (full gold) to detect whether the target band was present.

[0085] (3) Tobacco transient expression

[0086] Agrobacterium was added to 50 mL of LB liquid medium containing 50 μg / mL kanamycin, 50 μg / mL gentamicin and 25 μg / mL rifampicin, and then cultured on a shaker at 200 rpm for 36 hours.

[0087] The 50 mL centrifuge tubes containing Agrobacterium cells transformed with pEAQ-tHMGR, pEAQ-BcBAS1 and pEAQ-CYP716A41 vectors were centrifuged at 5000 rpm for 10 minutes in a 50 mL refrigerated centrifuge.

[0088] After centrifugation, pour off the supernatant, add 10 mL of tobacco infection solution, vortex and resuspend. Place the centrifuge tube in the centrifuge again and centrifuge under the above conditions.

[0089] After centrifugation, pour off the supernatant, add 10 mL of tobacco infection solution again, and vortex to resuspend.

[0090] The OD value of the shaken bacterial solution was measured at 600 nm on a UV spectrophotometer.

[0091] Four controls were set up, namely tHMGR (containing only Agrobacterium transformed with pEAQ-tHMGR vector), tHMGR+BcBAS1 (containing Agrobacterium transformed with pEAQ-tHMGR vector and Agrobacterium transformed with pEAQ-BcBAS1 vector), tHMGR+CYP716A41 (containing Agrobacterium transformed with pEAQ-tHMGR vector and Agrobacterium transformed with pEAQ-CYP716A41 vector), tHMGR+BcBAS1+CYP716A41 (containing Agrobacterium transformed with pEAQ-tHMGR vector, Agrobacterium transformed with pEAQ-BcBAS1 vector and Agrobacterium transformed with pEAQ-CYP716A41 vector). When infecting Agrobacterium, the OD value of each bacterial solution is required to be 0.2, so when the bacterial solution is combined in different ways, the OD value of each Agrobacterium contained in the bacterial solution is guaranteed to be 0.2. Dilute the tobacco infection solution. Use a syringe needle to scratch the back epidermis of the tobacco leaf, and then use a syringe to push the bacterial solution into the leaf. The bacterial solution is required to fill the entire leaf. Each plant is used as a biological replicate, that is, each control group corresponds to three tobacco leaves. After 6 days, the leaves are harvested and prepared into tobacco samples for GC-MS analysis.

[0092] (4) Tobacco sample preparation

[0093] Weigh 10mg freeze-dried tobacco leaf sample, then saponify in 1mL saponification reagent (10% [w / v] KOH, 90% [v / v] ethanol) containing 10μg / mL fecal triol (Sigma-Aldrich) (internal standard), and continue heating at 75°C for 1 hour. Then open the lid and heat the sample for another hour to evaporate the ethanol. 0.5mL ethyl acetate is added to the resulting product and vortexed. Then 0.5mL water is added and vortexed again. The solution is then centrifuged to promote the separation of ethyl acetate and water. Take 50μL ethyl acetate solution and dry it with N2, and use 50μL trimethylsilyl imidazole / pyridine reagent (Sigma-Aldrich) at 70°C for 30 minutes.

[0094] (5) GC-MS detection of metabolites

[0095] The reaction solution was analyzed using a GCMS-QP2020 instrument (Shimadzu) equipped with a SH-Rxi-5Sil MS capillary column (30 m × 0.25 mm × 0.25 μm, Shimadzu), with the electron energy set to 70 eV. The reactants obtained in step (4) were placed in an incubation chamber at an initial temperature of 180°C for 1 minute. The temperature was then increased to 20°C min -1The temperature was then raised from 180°C to 280°C at a rate of 5°C min-1 and held for 5 min. Subsequently, the temperature was raised from 280°C to 300°C at a rate of 5°C min-1. Metabolite quantification was performed using the external standard method after correction by comparing the peak areas of the metabolites with those of the internal standard coprosterol using peak area measurement.

[0096] The results are as follows Figure 6 As shown in the figure, compared with the control group expressing only the tHMGR gene, no new product was detected in the experimental group co-expressing CC2-CYP716A41. Co-expression of tHMGR and BcBAS1 genes produced a new compound 1 at 14.6 minutes. The elution time of compound 1 was the same as that of the β-amyrin standard. The mass spectrometry results of the two were compared, and compound 1 was identified as β-amyrin.

[0097] Under the condition of expressing tHMGR+BcBAS1 gene, co-expression of CC2-CYP716A41 gene will produce two new compounds 2 and 3. Compound 2 has the same peak time as the erythrodiol standard. Comparison of the mass spectrometry results of the two, compound 4 was identified as erythrodiol. Compound 3 has the same peak time as the oleanolic acid standard. Comparison of the mass spectrometry results of the two, compound 7 was identified as oleanolic acid. The structural difference between erythrodiol and oleanolic acid is at the C28 position, erythrodiol is a hydroxyl group, oleanolic acid is a carboxyl group, and the hydroxyl group can be further oxidized to a carboxyl group. Therefore, CYP716A41 can catalyze β-amyrin to produce erythrodiol, and can further catalyze the oxidation of erythrodiol to oleanolic acid.

[0098] Example 4

[0099] The catalytic efficiency of CYP716A41 obtained in Example 2 was identified as follows:

[0100] CYP716A41 of Chuanbei Chai No. 1 and Chuanbei Chai No. 2 was cloned and constructed into the pEAQ vector according to the methods of Examples 2 and 3. At the same time, the gene CYP716A75 with similar modification function reported in the literature (Moses T, Pollier J, Faizal A, Apers S, Pieters L, Thevelein JM, Geelen D, Goossens A. Unraveling the triterpenoid saponin biosynthesis of the African shrub Maesa lanceolata. Mol Plant. 2015 Jan; 8 (1): 122-35.) was also constructed into the pEAQ vector according to the method of Example 3. Subsequently, according to the method of Example 3, CYP716A41 and CYP716A75 of Chuanbei Chai No. 1 and Chuanbei Chai No. 2 were transformed into GV3101 Agrobacterium, respectively, and then co-infected with Agrobacterium containing tHMGR and BcBAS1 into tobacco for heterologous expression, and GC-MS samples were prepared for detection to compare the catalytic efficiency of CYP716A41 and CYP716A75 of the two genotypes of Bupleurum in producing erythrodiol.

[0101] The results show that ( Figure 7 ), the amount of erythrodiol produced by CYP716A41 of Chuanchai No. 2 in tobacco leaves was significantly higher than that of CYP716A41 and CYP716A75 of Chuanbeichai No. 1, reaching 9.45±0.15 mg of erythrodiol per gram of tobacco leaves (dry weight).

[0102] In summary, the present invention confirms that CYP716A41 is involved in the synthesis of erythrodiol, and erythrodiol can produce various C-28 hydroxylated oleanane-type saikosaponins and other C-28 hydroxylated site triterpenoids under the subsequent post-modification of CYP450 enzymes and UGT enzymes. Therefore, the CYP716A41 of the present invention further promotes the analysis of the saikosaponin biosynthetic pathway and synthetic biology research, and has important research value for the synthesis and regulation of oleanane-type pentacyclic triterpenoids such as saikosaponins. In addition, the cytochrome P450 oxidase gene CYP716A41 of the bupleurum and the recombinant host cell containing the gene are expected to be applied to the breeding of bupleurum plants.

[0103] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A Bupleurum cytochrome P450 oxidase gene, It is characterized in that The Bupleurum cytochrome P450 oxidase gene comes from Chuanchai No. 2, and the CDS region nucleotides and CDS region nucleotide reverse complementary sequences of the Bupleurum cytochrome P450 oxidase gene are shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

2. A Bupleurum cytochrome P450 oxidase gene, It is characterized in that The cytochrome P450 oxidase gene of Bupleurum chinense comes from Chuanbei Chai No. 1, and the CDS region nucleotides and the reverse complementary sequence of the CDS region nucleotides of the Bupleurum chinense cytochrome P450 oxidase gene are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

3. The amino acids encoding the Bupleurum cytochrome P450 oxidase gene according to claim 1, It is characterized in that The amino acid has the sequence shown in SEQ ID NO:

1.

4. The amino acids encoding the Bupleurum cytochrome P450 oxidase gene according to claim 2, It is characterized in that The amino acid has the sequence shown in SEQ ID NO:

4.

5. Expression vector, It is characterized in that Contains the Bupleurum cytochrome P450 oxidase gene according to claim 1 or 2.

6. Recombinant host cells, It is characterized in that It comprises the Bupleurum cytochrome P450 oxidase gene according to claim 1 or 2, or the expression vector according to claim 5.

7. The recombinant host cell according to claim 6, It is characterized in that The cell is selected from the group consisting of bacteria, fungal cells, insect cells, mammalian cells or plant cells.

8. Use of the Bupleurum cytochrome P450 oxidase gene according to claim 1 or 2, or the amino acid according to claim 3 or 4, or the expression vector according to claim 5, or the recombinant host cell according to claim 6 or 7 in catalyzing the hydroxylation reaction at C-28 of β-amyrin and / or catalyzing the carboxylation reaction at C-28 of erythrodiol.

9. Use of the Bupleurum cytochrome P450 oxidase gene according to claim 1 or 2, or the amino acid according to claim 3 or 4, or the expression vector according to claim 5, or the recombinant host cell according to claim 6 or 7 in synthesizing erythrodiol and / or oleanolic acid and / or oleanane-type Bupleurum saponin.

10. Use of the Bupleurum cytochrome P450 oxidase gene of claim 1 or 2, or the amino acid of claim 3 or 4, or the expression vector of claim 5, or the recombinant host cell of claim 6 or 7 in Bupleurum plant breeding.

Citation Information

Patent Citations

  • CYP450 zymoprotein for catalyzing 16 alpha-site hydroxylation of beta-amyrin as well as coding gene and application of CYP450 zymoprotein

    CN116218799A

  • Oleanane pentacyclic triterpenoid C-22 hydroxylase and application thereof

    CN117487771A

  • Coding gene of beta-amyrin synthase, protein and application of beta-amyrin synthase

    CN118308341A

  • Cytochrome P450 monooxygenases

    US20030041346A1

  • Saponarioside biosynthetic enzymes

    WO2024003012A1